{"id":"tqc3721-suspension-for-inhalation","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dyspnea"},{"rate":"null","effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of TQC3721 is not publicly available, but it is believed to work by affecting the respiratory system to alleviate symptoms of a particular disease.","oneSentence":"TQC3721 suspension for inhalation is a medication that targets the respiratory system to treat a specific condition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:36.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT07464587","phase":"PHASE3","title":"Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":800},{"nctId":"NCT07147946","phase":"PHASE3","title":"Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":666},{"nctId":"NCT05292196","phase":"PHASE2","title":"A Phase II Clinical Trial of TQC3721 Suspension for Inhalation","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-05-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":59},{"nctId":"NCT05987371","phase":"PHASE2","title":"A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-23","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":75},{"nctId":"NCT06527144","phase":"PHASE2","title":"A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-09-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT05051930","phase":"PHASE1","title":"A Clinical Trial of TQC3721 Suspension for Inhalation","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-10-18","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQC3721 suspension for inhalation","genericName":"TQC3721 suspension for inhalation","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQC3721 suspension for inhalation is a medication that targets the respiratory system to treat a specific condition. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}